Weekly Irinotecan Liposomes in Recurrent or Refractory Ewing Sarcoma — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Weekly Irinotecan Liposomes in Recurrent or Refractory Ewing Sarcoma — Stella

Home/Ewing Sarcoma/

View on ClinicalTrials.gov

Recruiting

Back to Ewing Sarcoma trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(3 sites)

China

Shandong Cancer Hospital and Institute, Jina, Shandong

Peking University People's Hospital, Beijin

Peking University Shougang Hospital, Beijing

Key details

Phase

Early testing

Sponsor

Peking University People's Hospital

Collaborators

Peking University Shougang Hospital, Shandong Cancer Hospital and Institute

Enrollment target

~44 participants

Started

March 2024

Primary completion

March 2026

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

8 Years – 40 Years

Last updated April 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.